Study details
Enrolling now
A First-in-Human Single and Multiple Ascending Dose Study of MT-701
Mirador Therapeutics, Inc.
NCT IDNCT07396909ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
19–55
Locations
1 site in CA
What this study is about
This Phase 1 study is focused on people with healthy volunteers. The primary outcome being measured is Number of Subjects with non-SAEs and SAES.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Number of Subjects with non-SAEs and SAES